TYK MEDICINES-B (02410): Positive Clinical Data on Multiple CDK Inhibitors Presented at ESMO 2025

Stock News

Oct 21, 2025

TYK MEDICINES-B (02410) announced that its board is pleased to share early clinical research results for three cell cycle-dependent kinase inhibitors (CDK inhibitors), TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i). These results were showcased in poster presentations at the European Society for Medical Oncology (ESMO) Annual Congress 2025, held from October 17-21, 2025, in Berlin, Germany. As one of the most influential academic events in the field of oncology worldwide, the ESMO congress attracts leading experts and scholars, providing a platform for discussing clinical challenges and sharing cutting-edge advancements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1149235188"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149235188\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149235188?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149235188","market":"fut","top_or_hot":-1,"title":"TYK MEDICINES-B (02410): Positive Clinical Data on Multiple CDK Inhibitors Presented at ESMO 2025","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) announced that its board is pleased to share early clinical research results for three cell cycle-dependent kinase inhibitors (CDK inhibitors), TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i). These results were showcased in poster presentations at the European Society for Medical Oncology (ESMO) Annual Congress 2025, held from October 17-21, 2025, in Berlin, Germany. As one of the most influential academic events in the field of oncology worldwide, the ESMO congress attracts leading experts and scholars, providing a platform for discussing clinical challenges and sharing cutting-edge advancements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK MEDICINES-B (02410): Positive Clinical Data on Multiple CDK Inhibitors Presented at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK MEDICINES-B (02410): Positive Clinical Data on Multiple CDK Inhibitors Presented at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-21 20:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) announced that its board is pleased to share early clinical research results for three cell cycle-dependent kinase inhibitors (CDK inhibitors), TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i). These results were showcased in poster presentations at the European Society for Medical Oncology (ESMO) Annual Congress 2025, held from October 17-21, 2025, in Berlin, Germany. As one of the most influential academic events in the field of oncology worldwide, the ESMO congress attracts leading experts and scholars, providing a platform for discussing clinical challenges and sharing cutting-edge advancements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159938","symbol_name":"医药","start_time":0,"source_url":"","article_id":"1149235188","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149235188","pubTimestamp":1761048849,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) announced that its board is pleased to share early clinical research results for three cell cycle-dependent kinase inhibitors (CDK inhibitors), TYK-00540 (CDK2/4i), TY-2699a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","02410":"同源康医药-B"},"translate_title":"泰克医药-B(02410)：在ESMO 2025上展示了多种CDK抑制剂的积极临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02410":1,"09939":1},"content_text":"TYK MEDICINES-B (02410) announced that its board is pleased to share early clinical research results for three cell cycle-dependent kinase inhibitors (CDK inhibitors), TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i). These results were showcased in poster presentations at the European Society for Medical Oncology (ESMO) Annual Congress 2025, held from October 17-21, 2025, in Berlin, Germany. As one of the most influential academic events in the field of oncology worldwide, the ESMO congress attracts leading experts and scholars, providing a platform for discussing clinical challenges and sharing cutting-edge advancements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}